Intended for UK Healthcare Professionals. Prescribing Information and Adverse Events reporting can be accessed in the footer of the site.

Migraine Space

Unpacking the psychological impact of headaches and migraines

Dr Giorgio Lambru discusses psychological comorbidities

From Head Start's Annual Meeting, June 2024

Dr Giorgio Lambru discusses psychological comorbidities including insomnia, anxiety, and depression in migraine patients, emphasising the importance of a holistic biopsychosocial approach to address patients’ unmet needs in migraine therapy.¹

Dr Lambru highlights findings from the UNITE study, which suggest that patients treated with fremanezumab for migraines might also experience improvement in their depression symptoms.^2,3

Prescribing Information

References:

1. Dudeney J, et al. Are psychological interventions efficacious for adults with migraine? A systematic review and meta-analysis. Headache. 2022;62(4):405-419. doi:10.1111/head.14260

2. Lipton RB, et al. Efficacy of fremanezumab treatment in reducing monthly migraine days in patients with migraine and major depressive disorder: Results from the UNITE study. Presented at World Congress of Neurology (WCN); 15–19 October 2023; Montreal.

3. Lipton RB, et al. Efficacy of fremanezumab in reducing depression in patients with migraine and major depressive disorder: results of the UNITE study. Presented at World Congress of Neurology (WCN); 15–19 October 2023; Montreal.

Date of Preparation: December 2025 | D: MIG-GB-00922 / T: MIG-GB-00980 / M: MIG-GB-00981
Teva UK Limited, Ridings Point, Whistler Drive, Castleford, WF10 5HX